ImmunityBio's Record Rally Enters Overbought Territory as Insider Sales Mount and FDA Warning Stings
Published on 07/03/2026 at 03:13 | Redaktion boerse-global.de
Insider selling has cast a shadow over ImmunityBio's breathtaking run. Morgan Stanley filed a Form 144 with the SEC on Thursday, flagging the possible sale of nearly 56,000 shares on behalf of company executives. The securities were drawn from freshly exercised options, alongside roughly 75,000 restricted shares originally granted in 2021. While such filings do not mandate an immediate sale and often serve tax planning purposes, they are amplifying jitters among retail investors already rattled by a regulatory spat and a stock trading near all-time highs.
The shares have surged 375% year-to-date, a gain of more than 360% that has pushed the company's market value to nearly $9 billion. But the rally is showing signs of exhaustion: the 14-day relative strength index sits at 74, firmly in overbought territory, and the stock now trades a quarter above its 50-day moving average. Annualized volatility of roughly 63% underscores the wild swings. Despite hitting a high of 10.54 euros earlier, the stock closed at 8.25 euros – a gap that suggests profit-taking may accelerate if the FDA's upcoming decision disappoints.
The regulatory backdrop remains tense. Founder Patrick Soon-Shiong has shot back at the U.S. health regulator over a spring warning about misleading marketing for the cancer drug Anktiva. The company insists the disputed television spot was never actually aired – only a script was submitted for review – and ImmunityBio has since removed certain digital content, including a podcast, as a goodwill gesture. Management has now filed a formal compliance response. On a brighter operational note, the Saudi Arabian health authority granted accelerated approval for Anktiva in lung cancer, adding a new geography to the drug's commercial footprint.
Should investors sell immediately? Or is it worth buying ImmunityBio?
Investors are now laser-focused on the next catalyst: a final FDA decision on Anktiva for papillary bladder cancer, expected in January 2027. ImmunityBio resubmitted its application for this indication in March 2026. Success would dramatically boost the drug's revenue, which last year reached $113 million. Meanwhile, the company's ascent into the Russell 1000 index at the end of June forced passive funds to buy the stock, but insider sales totaling $5.7 million over the past twelve months suggest those at the top are hedging their bets. Until the FDA delivers its verdict, the stock remains a high-stakes bet on a single drug and the credibility of its embattled management.
Ad
ImmunityBio Stock: New Analysis - 3 July
Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
